CALySSEY

Chimeric Antigen Receptor Treatment Targeting Lymphoma, Myeloma and Solid Tumors That Express CD70 (SEventY) CALySSEY

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
88 patients (estimated)
Tags
CAR T Cell, CD70
Trial Type
Treatment
Last Update
SparkCures ID
2207
NCT Identifier
NCT07297160

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 788-8038

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.